These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33201882)

  • 21. Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex.
    Oliveira JS; de Sousa EH; de Souza ON; Moreira IS; Santos DS; Basso LA
    Curr Pharm Des; 2006; 12(19):2409-24. PubMed ID: 16842188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent Advances and Structural Features of Enoyl-ACP Reductase Inhibitors of Mycobacterium tuberculosis.
    Inturi B; Pujar GV; Purohit MN
    Arch Pharm (Weinheim); 2016 Nov; 349(11):817-826. PubMed ID: 27775177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the inhibitory activity of (aza)isoindolinone-type compounds: toward in vitro InhA action, Mycobacterium tuberculosis growth and mycolic acid biosynthesis.
    Chollet A; Stigliani JL; Pasca MR; Mori G; Lherbet C; Constant P; Quémard A; Bernadou J; Pratviel G; Bernardes-Génisson V
    Chem Biol Drug Des; 2016 Nov; 88(5):740-755. PubMed ID: 27301022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid.
    Parikh SL; Xiao G; Tonge PJ
    Biochemistry; 2000 Jul; 39(26):7645-50. PubMed ID: 10869170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inoculum-dependent bactericidal activity of a
    Berube B; Deshpande A; Bhagwat A; Parish T
    Microbiology (Reading); 2023 Jun; 169(6):. PubMed ID: 37334886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.
    Saharan VD; Mahajan SS
    Bioorg Med Chem Lett; 2017 Feb; 27(4):808-815. PubMed ID: 28117201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of hydrazone containing thiadiazoles as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
    Doğan H; Doğan ŞD; Gündüz MG; Krishna VS; Lherbet C; Sriram D; Şahin O; Sarıpınar E
    Eur J Med Chem; 2020 Feb; 188():112035. PubMed ID: 31951850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds.
    Pan P; Tonge PJ
    Curr Top Med Chem; 2012; 12(7):672-93. PubMed ID: 22283812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time-dependent diaryl ether inhibitors of InhA: structure-activity relationship studies of enzyme inhibition, antibacterial activity, and in vivo efficacy.
    Pan P; Knudson SE; Bommineni GR; Li HJ; Lai CT; Liu N; Garcia-Diaz M; Simmerling C; Patil SS; Slayden RA; Tonge PJ
    ChemMedChem; 2014 Apr; 9(4):776-91. PubMed ID: 24616444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacophore mapping, molecular docking, chemical synthesis of some novel pyrrolyl benzamide derivatives and evaluation of their inhibitory activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
    Joshi SD; Dixit SR; Basha J; Kulkarni VH; Aminabhavi TM; Nadagouda MN; Lherbet C
    Bioorg Chem; 2018 Dec; 81():440-453. PubMed ID: 30223149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rational design of InhA inhibitors in the class of diphenyl ether derivatives as potential anti-tubercular agents using molecular dynamics simulations.
    Kamsri P; Koohatammakun N; Srisupan A; Meewong P; Punkvang A; Saparpakorn P; Hannongbua S; Wolschann P; Prueksaaroon S; Leartsakulpanich U; Pungpo P
    SAR QSAR Environ Res; 2014; 25(6):473-88. PubMed ID: 24785640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Formulation studies of InhA inhibitors and combination therapy to improve efficacy against Mycobacterium tuberculosis.
    Knudson SE; Cummings JE; Bommineni GR; Pan P; Tonge PJ; Slayden RA
    Tuberculosis (Edinb); 2016 Dec; 101():8-14. PubMed ID: 27865404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemical synthesis and in silico molecular modeling of novel pyrrolyl benzohydrazide derivatives: Their biological evaluation against enoyl ACP reductase (InhA) and Mycobacterium tuberculosis.
    Joshi SD; More UA; Dixit SR; Balmi SV; Kulkarni BG; Ullagaddi G; Lherbet C; Aminabhavi TM
    Bioorg Chem; 2017 Dec; 75():181-200. PubMed ID: 28961440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and synthesis of 9H-fluorenone based 1,2,3-triazole analogues as Mycobacterium tuberculosis InhA inhibitors.
    Suresh A; Srinivasarao S; Agnieszka N; Ewa AK; Alvala M; Lherbet C; Chandra Sekhar KVG
    Chem Biol Drug Des; 2018 Jun; 91(6):1078-1086. PubMed ID: 29063733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.
    He X; Alian A; Ortiz de Montellano PR
    Bioorg Med Chem; 2007 Nov; 15(21):6649-58. PubMed ID: 17723305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis, antimycobacterial activity and influence on mycobacterial InhA and PknB of 12-membered cyclodepsipeptides.
    Laqua K; Klemm M; Richard-Greenblatt M; Richter A; Liebe L; Huang T; Lin S; Guardia A; Pérez-Herran E; Ballell L; Av-Gay Y; Imming P
    Bioorg Med Chem; 2018 Jul; 26(12):3166-3190. PubMed ID: 29706526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The mutations of katG and inhA genes of isoniazid-resistant Mycobacterium tuberculosis isolates in Taiwan.
    Tseng ST; Tai CH; Li CR; Lin CF; Shi ZY
    J Microbiol Immunol Infect; 2015 Jun; 48(3):249-55. PubMed ID: 24184004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of mutations associated with isoniazid resistance in multidrug-resistant Mycobacterium tuberculosis clinical isolates.
    Jagielski T; Bakuła Z; Roeske K; Kamiński M; Napiórkowska A; Augustynowicz-Kopeć E; Zwolska Z; Bielecki J
    J Antimicrob Chemother; 2014 Sep; 69(9):2369-75. PubMed ID: 24855126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Probing mechanisms of resistance to the tuberculosis drug isoniazid: Conformational changes caused by inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis.
    Kruh NA; Rawat R; Ruzsicska BP; Tonge PJ
    Protein Sci; 2007 Aug; 16(8):1617-27. PubMed ID: 17600151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.